PDS Biotech colorectal cancer cohort in NCI-led Phase 2 trial of PDS01ADC meets criteria for Stage 2 expansion

PDS Biotechnology Corp

Stage 1 of NCI-led Phase 2 trial for PDS01ADC + FUDR/HAIP in metastatic colorectal cancer met RECIST v1.1 criteria for expansion.
6 of 9 patients achieved objective response in Stage 1, triggering Simon two-stage design expansion to up to 22 patients.
Enrollment in Stage 2 for colorectal cancer cohort underway; completion targeted by Q4 2025.
Two other cohorts (cholangiocarcinoma, adrenocortical cancer) continue enrolling in Stage 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.